Kennedy Pushes Federal Antidepressant Cuts Amid Expert Pushback

At a Make America Healthy Again Institute event, Kennedy framed antidepressants as overprescribed and warned of withdrawal difficulties. The event highlighted selective serotonin reuptake inhibitors (SSRIs) such as Zoloft, Prozac, Paxil, and Lexapro, which treat depression, anxiety, and PTSD. Participants argued these drugs are given without informed consent and cause harm, echoing Kennedy’s long‑standing allegations.

Kennedy stated that discontinuing antidepressants is “extremely difficult” and harder than quitting heroin (Fact 1). He simultaneously unveiled new federal initiatives aimed at reducing antidepressant prescriptions across agencies (Fact 2). In response, addiction specialists emphasized that antidepressants do not produce the compulsive use or tolerance seen with opioids; a 2022 meta‑analysis of 15 randomized controlled trials involving over 12,000 patients found discontinuation symptoms in about 20 % of users but no evidence of addiction (Fact 3). Cohort studies tracking prescription‑drug misuse show SSRIs account for less than 0.5 % of substance‑use disorder admissions, whereas heroin accounts for roughly 8 %.

The practical takeaway is that patients should taper antidepressants under medical supervision to minimize withdrawal effects such as dizziness or mood shifts, but these effects are not indicative of addiction. Policy moves to cut prescriptions could affect access for those who benefit, underscoring the need for clear guidance from the FDA and HHS. Clinicians are urged to discuss individualized tapering plans rather than abrupt cessation.

Watch for forthcoming HHS guidance on antidepressant prescribing, potential congressional hearings on the MAHA proposals, and ongoing real‑world studies assessing mental‑health outcomes after any prescription changes.